Class / Patent application number | Description | Number of patent applications / Date published |
424232100 | Poxviridae (e.g., smallpox virus, avian pox virus, fowlpox virus, rabbit myxoma virus, vaccinia virus, etc.) | 29 |
20080226678 | Compositions for Immunizing Against Mycobacterium - A method for generating a T cell immune response in a host involving administering a vectored vaccine comprising a non-replicating or replication impaired viral vector expressing the translation product of a mycobacterial antigen 85A gene. Vectored vaccines and uses thereof are also provided. Also provided is a method of inducing a CD8 and a CD4 memory T cell response against an antigen using an adenovirus vector expressing an antigen or an immunogenic fragment thereof. | 09-18-2008 |
20090047307 | Chemo-Immunotherapy Method - A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent. | 02-19-2009 |
20090068225 | COMPOSITIONS AND METHODS FOR ORTHOPOX VIRUS VACCINATION - The present invention relates to methods and compositions for stimulating an immune response. Specifically, the present invention provides methods of inducing an immune response to an orthopox virus (e.g., vaccinia virus) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., a nanoemulsion comprising vaccinia virus). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination) and research applications. | 03-12-2009 |
20090087454 | Method for therapeutic, clinical and veterinary use Poly-ICLC - We disclose here a method for using Poly-ICLC to prevent and/or treat certain human and veterinary infectious, neoplastic and autoimmune disorders, as well as for regulating a broad variety of genes in humans, consisting of use of poly-ICLC repeatedly and at low doses, alone or in combination with other drugs or vaccines. As such it represents an example of broad spectrum host-targeted therapeutics, in contrast to conventional antibiotics, antiviral or antineoplastic agents that target specific organisms or tumors. | 04-02-2009 |
20090263425 | METHODS OF STIMULATING AN IMMUNE RESPONSE AGAINST PROSTATE SPECIFIC ANTIGEN - The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for eliciting an immune response against PSA comprising administering (i) a priming inoculation of a first recombinant virus encoding PSA-OP and (ii) one or more boosting inoculations of a second recombinant virus encoding PSA-OP, wherein the first and second recombinant viruses are from a different genus. | 10-22-2009 |
20100008953 | PROCESS FOR PRODUCING POXVIRUSES AND POXVIRUS COMPOSITIONS - The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament. | 01-14-2010 |
20100112001 | PURIFICATION OF VACCINIA VIRUS- AND RECOMBINANT VACCINIA VIRUS-BASED VACCINES - The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production. | 05-06-2010 |
20100119551 | Methods and reagents for vaccination which generate a CD8 T cell immune response - New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition. | 05-13-2010 |
20100119552 | PURIFICATION OF VACCINIA VIRUSES USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY - The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production. | 05-13-2010 |
20100129403 | RECOMBINANT VIRAL VACCINE - The present invention concerns new recombinant viral vaccines. In particular the present invention provides combination products that comprise recombinant viral vectors and specific compounds able to improve the immune response raised in vivo by said recombinant viral vectors. | 05-27-2010 |
20100129404 | IMMEDIATE PROTECTION AGAINST PATHOGENS VIA MVA - The invention relates to methods and kits comprising poxviruses including, but not limited to modified vaccinia virus Ankara (MVA) and uses thereof to provide immediate protection against pathogens. Poxviruses including, but not limited to MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen. | 05-27-2010 |
20100136056 | NOVEL INSERTION SITES IN POX VECTORS - The present invention provides novel insertion sites for introducing DNA into pox vectors. | 06-03-2010 |
20100183672 | PROCESS FOR PREPARING LIVE SMALLPOX VACCINE - A safer live smallpox vaccine, which contains a lowered content of revertants, is provided. A process for manufacturing a live smallpox vaccine which comprises steps of: inoculating a master seed solution of an attenuated vaccinia virus to an appropriate number of containers (1 to n wherein n is an integer) of rabbit kidney cells and incubating them; inoculating a portion of the cultured solution obtained from each container to RK-13 cells and to Vero E6 cells and incubating them to thereby select containers which contain a cultured solution that forms plaques in RK-13 cells but not in Vero E6 cells; and preparing a drug substance of vaccine using the aforementioned cultured solution (working seed solution), and a live smallpox vaccine prepared in the aforementioned process. | 07-22-2010 |
20100189747 | Compositions and methods for treating or preventing hiv infection - The present invention provides methods and compositions for treating and/or preventing HIV infection in a subject in need thereof. It features the use of poxviruses, such as vaccinia virus, for therapy, prophylaxis, and diagnosis of HIV, as well as for any other medical or veterinary use associated with HIV or homologous viruses. The invention also provides for the use of poxviruses in the discovery of new agents to prevent and/or treat HIV infection. | 07-29-2010 |
20100255032 | Parapoxviruses in combination with other antiviral agents for the treatment of viral diseases - The present invention relates to the use of | 10-07-2010 |
20100285065 | MODIFIED CEA NUCLEIC ACID AND EXPRESSION VECTORS - The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid. | 11-11-2010 |
20100285066 | CANINE LEISHMANIA VACCINE - The present invention provides vectors that contain and express in vivo | 11-11-2010 |
20110014234 | MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMA VIRUSES - The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals. | 01-20-2011 |
20110064769 | VV PROMOTER-DRIVEN OVEREXPRESSION OF RECOMBINANT ANTIGENS - The present invention is directed to the use of a pharmaceutical composition comprising a vaccinia virus (VV) based vector construct under the control of a strong VV specific promoter. The present invention is in particular directed to the use of this pharmaceutical composition for the treatment of infectious diseases, chronic inflammatory or degenerative diseases, and cancer and for evoking an immune response against subdominant and/or cryptic epitopes. | 03-17-2011 |
20110212131 | METHOD FOR ENHANCING AN IMMUNE RESPONSE - A vaccine composition for combating Pox viridae viral infections in living organisms such as mammals (including humans) comprises TAP-1 and/or TAP-2 to augment the antigen processing capability of infected cells and hence their immunogenicity. The composition may be used alone or, preferably, as an immunogenicity-enhancing adjuvant with a pox antigen-based vaccine, especially in the treatment or prophylaxis of viral infections such as smallpox. | 09-01-2011 |
20110300181 | PURIFICATION OF VACCINIA VIRUS- AND RECOMBINANT VACCINIA VIRUS-BASED VACCINES - The present invention relates to methods for purification of Vaccinia viruses (W) and/or Vaccinia virus (W) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production. | 12-08-2011 |
20120009217 | MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES - The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals. | 01-12-2012 |
20120107359 | USE OF A MODIFIED POXVIRUS FOR THE RAPID INDUCTION OF IMMUNITY AGAINST A POXVIRUS OR OTHER INFECTIOUS AGENTS - The present invention relates to the rapid induction of a protective immune response against infectious agents using a poxvirus. An immune response can be induced by administering the poxvirus 7 to 2 days prior to infection with the infections agents. | 05-03-2012 |
20120276142 | NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IGE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME - Fusion proteins and nucleic acid molecules encoding fusion proteins are disclosed. Fusion proteins comprising non-IL-15 signal peptide linked to IL-15 protein sequences and fusion proteins comprising an IgE signal peptide linked to non-IgE protein sequences are disclosed. Vectors comprising such nucleic acid molecules; and to host cells comprising such vectors are disclosed as well as recombinant vaccines and live attenuated pathogens encoding fusion proteins, and methods of using the same, are disclosed. The immunomodulatory effect following delivery of IL-15 and CD40L, with or without immunogens, is disclosed as are various nucleic acid molecules and compositions thereof used for delivering such proteins and methods of using such compositions. | 11-01-2012 |
20130011436 | Methods and Compositions Containing Fc Fusion Proteins for Enhancing Immune Responses - Provided are compositions and methods for inhibiting cell growth. The cells that are targeted by the compositions and methods of the invention express an antigen, a mimotope of the antigen, or a CXCR4 chemokine receptor. The method entails administering to an individual a polynucleotide encoding an immunoglobulin Fc and an antigen expressed by the cells or a mimotope of the antigen. The method also involves administering to the individual a composition which contains a polynucleotide encoding an immunoglobulin Fc and an antagonist peptide of a CXCR4 chemokine receptor expressed by the cells. Also provided are proteins encoded by the polynucleotides. | 01-10-2013 |
20140044752 | INACTIVATED VIRUS COMPOSITIONS AND METHODS OF PREPARING SUCH COMPOSITIONS - The present invention is directed at a composition comprising a live swine flu virus having an infectious component and a plurality of surface antigens in contact with a formaldehyde donor agent having a molecular weight that is less than about 400 g/mol. Preferably, the formaldehyde donor agent is selected from a non-crosslinking chemical fixative that contains urea. | 02-13-2014 |
20140242115 | INACTIVATING PATHOGENS WITH OXIDIZING AGENTS FOR VACCINE PRODUCTION - The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided. | 08-28-2014 |
20150343046 | COMPOSITIONS, METHODS AND USES FOR EXPRESSION OF ENTEROBACTERIUM-ASSOCIATED PEPTIDES - Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, attenuated or modified vaccinia virus vectors expressing enterobacterial-associated peptides. In other embodiments, vaccine compositions are reported of use in a subject. | 12-03-2015 |
20160106829 | ATTENUATED VACCINIA VIRUS KVAC103 STRAIN - Disclosed herein is the attenuated vaccinia virus strain KVAC103 obtained by subculturing a vaccinia virus strain 103 times in VERO cells. The attenuated vaccinia virus strain KVAC103 has significantly low toxicity, shows reduced skin lesions, and, at the same time, induces effectively immune responses to poxvirus. Thus, it can be used as a poxvirus vaccine while causing less side effects. | 04-21-2016 |